United Laboratories International (HKG:3933) unit Zhuhai United Laboratories Zhongshan Branch obtained approval in China for certain marketing applications for its Tadalafil tablets.
The National Medical Products Administration granted three applications for the drug for erectile dysfunction and ED associated with benign prostatic hyperplasia, according to a Thursday filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments